Fig. 4.
Fig. 4. LTRC protection with AcSDKP in DOX-treated mice. (A) Male donor mice given saline, DOX alone, or in association with AcSDKP administred as a continuous infusion beginning 48 hours before the first DOX injection were killed on day 7. Various numbers of their BMCs were then injected into lethally irradiated female recipients. (A) Recipient mice survival at 5 months postgrafting, as a function of the dose of cells injected, *P < .02 (Student'st-test) between AcSDKP-DOX– and DOX-alone–treated mice. (B) Left panel: Y chromosome PCR analysis of peripheral leukocyte DNA from 7 female mice grafted with bone marrow from male donors given both AcSDKP and DOX. Right panel: Controls consisted of Y chromosome PCR analysis of DNA from a mixture of male and female BMCs (from 0% to 100% male cells) and were used for quantification of the data. Mixed chimerism (an average of 75% donor cells) was seen in all long-term survivors tested.

LTRC protection with AcSDKP in DOX-treated mice. (A) Male donor mice given saline, DOX alone, or in association with AcSDKP administred as a continuous infusion beginning 48 hours before the first DOX injection were killed on day 7. Various numbers of their BMCs were then injected into lethally irradiated female recipients. (A) Recipient mice survival at 5 months postgrafting, as a function of the dose of cells injected, *P < .02 (Student'st-test) between AcSDKP-DOX– and DOX-alone–treated mice. (B) Left panel: Y chromosome PCR analysis of peripheral leukocyte DNA from 7 female mice grafted with bone marrow from male donors given both AcSDKP and DOX. Right panel: Controls consisted of Y chromosome PCR analysis of DNA from a mixture of male and female BMCs (from 0% to 100% male cells) and were used for quantification of the data. Mixed chimerism (an average of 75% donor cells) was seen in all long-term survivors tested.

Close Modal

or Create an Account

Close Modal
Close Modal